We have joined with Serono to launch a study confirming the efficacy of the 75 IU dose of Luveris® versus placebo to achieve clinical pregnancy in women with WHO Type I amenorrhea, hypogonadotropic hypogonadism (HH) and profound luteinizing hormone (LH) deficiency.

"Luveris allows us to precisely tailor LH administration to individual patient needs, offering greater treatment flexibility," said Mark Perloe, MD, GRS Medical Director.

GRS is currently recruiting women between 18 and 40 years of age who have a clinical history of HH amenorrhea who desire pregnancy (failure to respond to progesterone withdrawal). The patient must have a Body Mass Index between 18.4 and 31.4 kg/m2 and have no prior treatment cycles with gonadotropins or GnRH. Potential study patients will undergo hormonal screening to determine eligibility. The following hormonal values are required for participation: FSH: <5 IU/L; LH: <1.2 IU/L; Prolactin: <43.3 ng/mL; TSH: <6.5 mcIU/mL; Free T4: 0.8-1.8 ng/dL; Testosterone: <1.0 ng/mL.

Eligible patients will be randomized to receive 25 IU Luveris, 75 IU Luveris or placebo. All patients will receive Gonal-F® at the recommended starting dose of 75-150 IU (adjustable up to 225IU). All study information will remain confidential and each participant will undergo an initial evaluation and receive assigned treatment and medication during the study cycles at no cost. Individuals interested in participating are invited to contact Tina Vincent at study@ivf.com or 404.843.2229 ext 151.

Reproductive Specialists applies medical science's most advanced fertility technologies to provide the highest standards of patient-centered, reproductive healthcare. The staff at GRS, including infertility laboratory pioneer Michael Tucker, Ph.D., focuses on providing individualized, innovative solutions for reproductive challenges and infertility, specializing in in vitro fertilization, intracytoplasmic sperm injection and other assisted reproductive technologies. Fellowship-trained reproductive endocrinologists Dr. Susan C. Conway, Dr. Carolyn Kaplan and Dr. Mark Perloe are experts in female and male disorders including polycystic ovary syndrome (PCOS), repeated pregnancy loss, menstrual disorders and azoospermia. GRS has three offices, Atlanta, Alpharetta and Decatur, to conveniently serve patients across Metro Atlanta. For more information about Georgia Reproductive Specialists, visit www.ivf.com.

ReliefInsite.com is a new company that, for the past four years, has been in the process of developing a secure web-based Electronic Pain Diary that can be used for monitoring any pain condition, including pelvic pain. The application consists of a dynamic body map (with front, back and side views) where you identify the location of your pain, its intensity and characteristics. In the application, you also record pain symptoms, medication, treatment, and lifestyle. One of the key features of the application is found in its Analysis section which provides graphs, charts, picture frames, a summation of notes, and animated video-like playback of all the readings you have entered. This information can be shared with your doctor or other individuals you specify.

If you are interested in being a test user of this application, please send an e-mail to fred.eberlein@reliefinsite.com. In your e-mail please include your pain condition, phone number and e-mail address. All inquiries about ReliefInsite.com must go through Fred Eberlein. Please do not contact GRS regarding information about this opportunity.